Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
OCULAR THERAPEUTIX, INC reported the quarter and year ended December 31, 2023 results: revenue approximately $57.9 million.
- Period
- the quarter and year ended December 31, 2023
- Revenue
- approximately $57.9 million
- Result
- preliminary results
Exact text from the filing
its preliminary, unaudited cash and cash equivalents were approximately $195.8 million as of December 31, 2023, and its preliminary, unaudited net product revenue for the year ended December 31, 2023, was approximately $57.9 million.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Pravin U. Dugel, M.D. was appointed as Executive Chairman at OCULAR THERAPEUTIX, INC.
- Action
- appointed
- Role
- Executive Chairman
Exact text from the filing
On February 20, 2024, Pravin U. Dugel, M.D., was appointed as Executive Chairman of the Company and as a Class III director, effective as of February 21, 2024
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
OCULAR THERAPEUTIX, INC entered into Securities Purchase Agreement with certain institutional accredited investors valued at approximately $325.0 million (effective 2024-02-21).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional accredited investors
- Value
- approximately $325.0 million
- Effective
- 2024-02-21
Exact text from the filing
On February 21, 2024, Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 32,413,560 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $7.52 per share and, to certain Investors in lieu of Shares, pre-funded warrants to purchase 10,805,957 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a price of $7.519 per Pre-Funded Warrant (the “Private Placement”).
View on SEC.gov